30913-86-1

Usage

Uses

Used in Pharmaceutical Research:
Methyl 4-(4-bromophenyl)-4-oxobutanoate is used as a reagent in pharmaceutical research for the preparation of various pharmaceutical products. Its unique chemical structure allows it to be a valuable component in the synthesis of new and existing drugs.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 4-(4-bromophenyl)-4-oxobutanoate is used as a reagent to facilitate the formation of complex organic molecules. Its versatility in reactions makes it a useful tool for chemists working on the development of new compounds.
Used in Industrial Applications:
Although not explicitly mentioned in the provided materials, Methyl 4-(4-bromophenyl)-4-oxobutanoate may also have applications in various industrial processes, such as the production of specialty chemicals, fragrances, or dyes, due to its fruity odor and chemical properties.
Safety Considerations:

Upstream product

• 32095-83-3 4-oxo-4-(4-bromo-phenyl)-cis-crotonic acid methyl ester 
• 67-56-1 methanol 
• 6340-79-0 4-oxo-4-(4-bromophenyl)butanoic acid 
• 292638-85-8 acrylic acid methyl ester 
• 108-86-1 bromobenzene 
• 851108-42-4 4-(4-bromophenyl)-4-oxobutanamide 
• 1490-25-1 succinic acid monomethylester chloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 922-67-8 propynoic acid methyl ester 
• 77086-38-5 ketene t-butyldimethylsilyl methyl acetal 
• 99-73-0 para-bromophenacyl bromide 
• 3878-55-5 methyl hydrogen succinate 
• 58824-56-9 1-(p-bromophenyl)prop-2-en-1-ol 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 6340-79-0 4-oxo-4-(4-bromophenyl)butanoic acid 
• 126135-40-8 methyl 4-hydroxy-4-(4-bromophenyl)butanoate 
• 90991-21-2 4-(4-cyano-phenyl)-4-oxo-butyric acid methyl ester 
• 509083-36-7 rac-1-(4-bromophenyl)-1,4-butandiol 
• 1357165-86-6 methyl 4-[4-(5-nitropyridin-2-yl)phenyl]-4-oxobutyrate 
• 405522-29-4 (3S,7aS)-7a-(4-bromophenyl)-3-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
• 405522-31-8 (R)-5-(4-bromophenyl)-1-((S)-2-hydroxy-1-phenylethyl)pyrrolidin-2-one 
• 405522-33-0 (R)-5-(4-bromophenyl)-1-((S)-2-chloro-1-phenylethyl)pyrrolidin-2-one 
• 405522-35-2 (R)-5-(4-bromophenyl)-1-(1-phenylvinyl)pyrrolidin-2-one 
• 1234387-31-5 (3S,5R)-3-allyl-5-(4-bromophenyl)-1-(2-(tert-butyldimethylsilyloxy)ethyl)pyrrolidin-2-one 
• 1234387-32-6 2-((3R,5R)-5-(4-bromophenyl)-1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxopyrrolidin-3-yl)acetaldehyde 
• 1234387-34-8 2-((3R,5R)-5-(4-bromophenyl)-1-(2-(tertbutyldimethylsilyloxy)ethyl)-2-oxopyrrolidin-3-yl)acetic acid 
• 1234387-36-0 2-((3R,5R)-5-(4-bromophenyl)-1-(2-(tertbutyldimethylsilyloxy)ethyl)-2-oxo-pyrrolidin-3-yl)-N-(3-chloro-2-methylphenyl)acetamide 
• 1234387-38-2 2-((3R,5R)-5-(4-bromophenyl)-1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxopyrrolidin-3-yl)-N-(4-(trifluoromethoxy)phenyl)acetamide 

Relevant academic research and scientific papers

One-Pot Sequential Photoredox Chemistry and Asymmetric Transfer Hydrogenation with a Single Catalyst

A sequential process is reported, in which different photoredox reactions are placed in sequence with asymmetric transfer hydrogenations of aryl ketones to provide a diverse set of chiral alcohols with enantioselectivities of up to 99 % ee. The method relies on a single chiral-at-metal catalyst which is added at the beginning of the two step sequence and only a final purification of the reaction product is required.

Biocatalytic Asymmetric Reduction of γ-Keto Esters to Access Optically Active γ-Aryl-γ-butyrolactones

An efficient stereoselective syntheses of a series of functionalized optically active γ-aryl-γ-butyrolactones is achieved by enzymatic asymmetric reduction of the corresponding sterically demanding γ-keto esters employing wild-type and recombinant alcohol dehydrogenases. The best stereoselectivities for the reduction via hydrogen transfer was obtained with two short chain dehydrogenases (SDRs) of complementary stereospecificity from Aromatoleum aromaticum, namely the Prelog-specific NADH-dependent (S)-1-phenylethanol dehydrogenase [(S)-PED] and the anti-Prelog-specific (R)-1-(4-hydroxyphenyl)-ethanol dehydrogenase [(R)-HPED], respectively.Biotransformations catalyzed by both enzymes, followed by TFA-catalyzed cyclization of the resulting γ-hydroxy esters, furnished the respective (S)- and (R)-configured products with exquisite optical purity (up to >99% ee). The synthetic value was demonstrated on preparative scale for the asymmetric bioreduction of the model compound, methyl 4-oxo-4-phenylbutanoate, affording optically pure (S)-γ-phenyl-γ-butyrolactone (>99% ee) in 67–74% isolated yield at 89–95% conversion depending on the applied scale. (Figure presented.).

Transition Metal-Free Alkyne-Aldehyde Reductive C?C Coupling trough Cascade Borylation/Olefin Isomerization

A direct approach to γ-keto esters through cascade alkyne-aldehyde reductive C?C coupling of propargyl esters and aromatic aldehydes under transition-metal-free (TM-free) fashion was developed. Compared with multistep processes, this procedure provides a

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

TBAI/TBHP-Promoted Generation of Malonyl Radicals: Oxidative Coupling with Styrenes Leads to γ-Keto Diesters

A metal-free protocol for oxidative coupling of malonic esters with styrenes to form γ-keto diesters has been developed. Key to the success of this process is the generation of malonyl radicals from unfunctionalized malonic esters under organo-catalysis conditions with TBAI and TBHP. This process tolerates both terminal and internal olefins with diverse malonic esters. It provides a new green metal-free alternative to traditional metal mediated process for generation of malonyl radicals and there by γ-keto diesters.

Organoselenium-catalyzed synthesis of oxygen- and nitrogen-containing heterocycles

A new and efficient approach for the synthesis of oxygen and nitrogen heterocycles by organoselenium catalysis has been developed. The exo-cyclization proceeded smoothly under mild conditions with good functional group tolerance and excellent regioselectivity. Mechanistic studies revealed that 1-fluoropyridinium triflate is key for oxidative cyclization.

Remote activation of the nucleophilicity of isatin

The concept of the remote activation of reactivity was first applied in asymmetric organocatalysis. An isatin 3-phenylimine derivative acts as a donor in the thiourea catalyzed asymmetric addition to unsaturated 1,4-ketoesters, affording aza-Michael adducts in high enantiomeric purity and yield.

Cross metathesis of allyl alcohols: How to suppress and how to promote double bond isomerization

Under standard conditions the cross metathesis of allyl alcohols and methyl acrylate is accompanied by the formation of ketones, resulting from uncontrolled and undesired double bond isomerization. By conducting the CM in the presence of phenol, the catalyst loading and the reaction time required for quantiative conversion can be reduced, and isomerization can be suppressed. On the other hand, consecutive isomerization can be deliberately promoted by evaporating excess methyl acrylate after completing cross metathesis and by adding a base or silane as chemical triggers.

NAPHTHALENE DERIVATIVE

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

AGENT FOR TREATMENT OF EYE DISEASES

The present invention provides agents effective to treat eye diseases, pharmaceutical compositions comprising them, methods for preparing pharmaceuticals for treatment of eye diseases comprising using the agents, use of the agents in manufacture of pharma